Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

421 articles

Keyword: hepatocellular carcinomaClear keyword

International journal of nanomedicine2026ReviewNon-viral Gene DeliveryDrug Delivery

1. Polymeric Nanomedicines for siRNA Delivery in Hepatocellular Carcinoma: Emerging Therapeutic Strategies, Combination Approaches, and Translational Perspectives

Thalij Km, You Hw, Habeeb M, Ratchagar Jv, Khot Vs, Gorde Pl

Hepatocellular carcinoma is the sixth most common cancer worldwide and a leading cause of cancer related mortality. Risk factors include chronic hepatitis B/C, obesity, alcohol abuse, diabetes and metabolic disorders. In advanced stages, normal treatments such as surgery, transplantation and chemotherapy are not as effective as tumors develop resistance and do not target oncogenic pathways well. Small interfering RNA (siRNA) therapeutics have the potential to change treatment paradigms by silencing specific biological pathways, thus suppressing tumor progression.

drug delivery hepatocellular carcinoma polymeric nanomedicines siRNA

Read the article

ACS applied bio materials2026ResearchDrug Delivery

2. Correlating the C-5 Induction Effect on Uracil-Based Nucleoside Lipid Nanoparticles for Enhanced Redox-Mediated Therapeutic Efficacy in Hepatocellular Carcinoma

Kumar A, Patri Sv, Chilumula S, Arjunan P, Ayyanar V, Hanchate P, Et Al.

The clinical effectiveness of doxorubicin (DOX) in hepatocellular carcinoma (HCC) remains constrained by poor tumor selectivity and the emergence of multidrug resistance. In this work, we examine how the electronic nature of the C-5 substituent on uracil-based nucleoside lipids shapes the physicochemical and biological behavior of DOX-loaded lipid nanoparticles (LNPs).

5-fluorouridine Doxorubicin Hepatocellular carcinoma apoptosis drug delivery ionizable lipids lipid nanoparticles α-tocopherol

Read the article

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through GMP supply.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes, licensing and GMP supply.InvestorsDownload our capabilities deckPlatform, pipeline milestones, manufacturing and partnership models in one PDF.